HLB제넥스
187420KOSDAQ69.5 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
HLB제넥스 is a biotech company founded in 2000, specializing in the development and production of customized enzymes and bio-healthcare materials using core technologies like microbial display and recombinant protein secretion. Its main business areas include industrial specialty enzymes, bio-healthcare materials, and microbiome-enzyme products, with key offerings such as eco-friendly catalase, lactase for GOS production, and nattokinase for cardiovascular health. The company is also advancing its pipeline drug GF103, an oral treatment for wet age-related macular degeneration, currently preparing for Phase I clinical trials.
Number of Employees
82people
Average Salary
57.5M KRW
Score Calculation Basis
Detailed Financial Score
Half of industry avg (excellent)
In line with industry avg
6.9x industry avg (excellent)
Half of industry avg (excellent)
Avg ▲26.8% (2-year basis)
Avg ▲122.2% (2-year basis)
Avg ROE -4.4% (improving, 3yr)
Detailed News Sentiment
- PositiveHLB, 진양곤 의장 등 주요 경영진 자사주 추가 매수…"책임경영 강화...
주요 경영진의 자사주 추가 매수로 책임경영 강화 신호, 긍정적 시장 반응 예상.
- NeutralHLB제넥스, '비타푸드 아시아 2026' 참가…"소디자임 소개"
HLB제넥스가 아시아 주요 식품 전시회에 참가하여 제품 소개 예정이나, 직접적인 시장 영향은 제한적입니다.
- PositiveHLB제넥스 "200억원 규모 전환사채 선제 취득"
HLB제넥스의 선제적 전환사채 취득은 재무 건전성 강화로 긍정적 평가를 받고 있다.
Detailed Momentum
52w lower range (29%)
1m +17.52% (strong rise)
Volume decreasing
Detailed Disclosure
- Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-08-14
- Neutral반기보고서 (2026.06)2026-08-13
